๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pilot study of ascorbic acid for the treatment of refractory immune thrombocytopenic purpura

โœ Scribed by Steven J. Jubelirer

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
229 KB
Volume
43
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Rituximab for treatment of refractory/re
Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)
โœ Afaq Ahmad; Anita Aggarwal; Daya Sharma; Harish P. Dave; Virginia Kinsella; Marg ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB ๐Ÿ‘ 2 views

## Abstract Plasma exchange is the standard treatment for thrombotic thrombocytopenic purpura (TTP). For patients refractory to plasma exchange, treatment options are limited and often unsuccessful. The platelet thrombi that form in acquired TTP are believed to result from the presence of procoagul

Rituximab for the treatment of refractor
Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases
โœ Lydia Koulova; Doru Alexandrescu; Janice P. Dutcher; Kevin P. O'Boyle; Saji Eape ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB ๐Ÿ‘ 2 views

Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp